Researchers developed the seats to measure biometrics during ‘natural’ processes
With 1 million new cases of congestive heart failure diagnosed each year, a revolutionary product is making it easier for hospitals to monitor patients with the condition in the comfort of their own homes.
A toilet-seat based cardiovascular monitoring system created by a team of Rochester Institute of Technology researchers, aims to lower the hospital readmission rates of patients with congestive heart failure. The toilet seats, which will be brought through the FDA clearance process by the researchers’ company Heart Health Intelligence, would be purchased by hospitals and issued to heart failure patients after discharge. The toilet seats are equipped to measure the electrical and mechanical activity of the heart, and can monitor heart rate, blood pressure, blood oxygenation levels, and the patient’s weight and stroke volume, which is the amount of blood pumped out of the heart at every beat. Algorithms analyze the data, and with further development, will alert advanced practice providers of a deteriorating condition. A report will be passed along to cardiologists who will then determine if intervention is necessary.
Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that developed the toilet seats.
“Typically, within 30 days of hospital discharge, 25 percent of patients with congestive heart failure are readmitted,” said Conn. “After 90 days of hospital discharge, 45 percent of patients are readmitted. And the Centers for Medicare and Medicaid Services is penalizing hospitals for readmitting patients for heart failure.”
Conn, the company’s chief executive officer, further explains that using the national average for readmission rates, the penalty alone for readmitting 150 patients is approximately $500,000 annually. The total cost of providing 150 patients with their own monitored toilet seats from HHI is $200,000. With that investment, he says, hospital systems will save more than double their initial investment within one year.
According to Conn, who earned three degrees from RIT—a bachelor’s degree and a master’s degree in electrical engineering in 2011 and 2013, respectively, and a doctoral degree in microsystems engineering in 2016—the system will pick up deteriorating conditions before the patients even realize they are symptomatic. And with the rapid data analysis, interventions can be as simple as a drug change or short office visit, instead of an admission to the hospital.
HHI, which joined RIT’s Venture Creations business incubator earlier this year, is now focused on moving the product forward. The team is heavily involved in writing grants for additional funding and networking, and human-subject testing and pre-clinical studies are well underway. Conn and his team are working on approving the product with the FDA and rolling it out across the country.
Learn more: Toilet seat that detects congestive heart failure getting ready to begin commercialization
The Latest on: Congestive heart failure
[google_news title=”” keyword=”congestive heart failure” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Congestive heart failure
- The heart of the matter: Heartworm disease in dogson April 26, 2024 at 11:31 pm
Immature heartworms enter through the skin when an infected mosquito bites the dog. These immature worms grow to adulthood, mate and produce offspring inside the dog, disturbing normal blood flow and ...
- 'Mind Your Heart' study to enroll patients diagnosed with heart failureon April 26, 2024 at 10:31 am
Swollen legs, ankles and shortness of breath are just a few of the symptoms of congestive heart failure.
- First generic pimobendan chewable tablets for canine congestive heart failure receives FDA approvalon April 26, 2024 at 6:44 am
The drug from Cronus Pharma contains the same active ingredient as Boehringer Ingelheim's Vetmedin.
- FDA fast tracks investigational gene therapy for heart failureon April 24, 2024 at 7:00 am
The US Food and Drug Administration (FDA) has granted Fast Track designation to invesigational gene therapy AB-1002 for treatment of congestive heart failure (CHF).AB-1002 is an ...
- Surgeons perform first combined heart pump and pig kidney transplanton April 24, 2024 at 6:00 am
The first transplant surgery to combine a mechanical heart pump as well as a gene-edited pig kidney has been completed at NYU Langone Health, the system said Wednesday.
- From the corral: Heart complicationson April 23, 2024 at 9:05 am
Sixty-six percent had normal hearts and 34% had signs of heart problems. When hearts are inspected on the viscera table, the signs of congestive heart failure are swelling of the heart. Cattle that ...
- Shari Belafonte shares last convo with dad Harry Belafonteon April 22, 2024 at 2:08 am
Show” actress previously shared that there were “no huge tears” when her father died of congestive heart failure The post Shari Belafonte shares last convo with dad Harry Belafonte appeared first ...
- Shari Belafonte Reveals the Last Thing Her Dad Harry Belafonte Said to Her: 'He Died Laughing' (Exclusive)on April 21, 2024 at 11:10 am
Shari Belafonte tells PEOPLE that her last memory of her father, Harry Belafonte, before his death in April 2023 at age 96 was of him laughing and joyful.
- Semaglutide: A Dominant Player for Patients With Heart Failureon April 19, 2024 at 2:53 am
Data provesSemaglutideefficacy in treatment of Type 2 diabetes, obesity, heart failure, and chronic kidney failure, it emerges as important therapy in metabolic syndrome.
- AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failureon April 18, 2024 at 5:31 am
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Not intended for UK MediaAB-1002 is being studied for ...
via Bing News